Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.

doi:10.3389/fimmu.2024.1493877

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.

Frontiers in immunology - 1 Jan 2024

Poddubskaya Elena, Suntsova Maria, Lyadova Marina, Luppov Daniil, Guryanova Anastasia, Lyadov Vladimir, Garazha Andrew, Sorokin Maksim, Semenova Anna, Shatalov Vitaly, Biakhova Maria, Simonov Alexander, Moisseev Aleksey, Buzdin Anton

Abstract excerpt

Background: Immune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need. Methods: We conducted a prospective observational study of the prognostic potential ofseveral existing and putative biomarkers of response to immunotherapy in acohort of...

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Male
Female
Prospective Studies
Immune Checkpoint Inhibitors
Biomarkers, Tumor
Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Middle Aged

Aged

B7-H1 Antigen

Immunotherapy

Programmed Cell Death 1 Receptor

Aged, 80 and over

Treatment Outcome

Adult

Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39723204
DOI: 10.3389/fimmu.2024.1493877
PMCID: PMC11669362

Genes

CD3G
NCAM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.PMID 39723204Read ↗

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerSemantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non-Small Cell Lung Cancer: A Nationwide CCAT Cohort From Japan.Semantic proximity Read ↗

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studySemantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinomaSemantic proximity Read ↗

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.Semantic proximity Read ↗

A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.